Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis

Without taking into account existing biomarkers like genetic mutations (BRCA mutation, Homologous recombination deficiency) with advanced ovarian cancer (OC), the overall survival (OS), progress-free survival (PFS) of the aggregate all groups that have been classified were hazard ratio (HR): 0.72, 95% confidence intervals (CI): 0.66-0.79 and HR: 0.48, 95%CI: 0.44-0.52, respectively. Meanwhile, the OS and PFS of the whole population (regardless of existing genetic mutation markers) were HR: 0.74, 95%CI: 0.64-0.87 and HR: 0.52, 95%CI: 0.42-0.65, separately. Furthermore, the OS and PFS of positive gene mutation markers were HR: 0.71, 95%CI: 0.61-0.83 (HRD and BRACm) and HR: 0.47, 95%CI: 0.42-0.52 (HRD and BRACm), individually. The poly ADP-ribose polymers (PARP) inhibitors have desired efficiency and security in the maintenance treatment of advanced OC patients with BRCAm or BRCAwt, HRD or HRP and unknown gene status.

Automated summary

Ignoring genetic mutations, the overall survival and progression-free survival of advanced ovarian cancer patients were significantly improved with a hazard ratio of 0.72 (95% CI: 0.66-0.79) and 0.48 (95% CI: 0.44-0.52) respectively. Regardless of existing genetic mutation markers, the overall survival and progression-free survival for the entire population showed a hazard ratio of 0.74 (95% CI: 0.64-0.87) and 0.52 (95% CI: 0.42-0.65) respectively. Moreover, positive gene mutation markers demonstrated a hazard ratio of 0.71 (95% CI: 0.61-0.83) for overall survival and 0.47 (95% CI: 0.42-0.52) for progression-free survival. Poly ADP-ribose polymers (PARP) inhibitors have shown efficacy and safety in maintaining treatment for advanced ovarian cancer patients with BRCAm or BRCAwt, HRD or HRP, and unknown gene status.